MedTrace Logo

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2011-10-07

Study results available
· View outcomes & findings →

Summary

The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.

Conditions

Interventions

DRUG

Dose Group 1

IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg

DRUG

MN-221 placebo

i.v. infusion of placebo for 15 minutes

DRUG

Dose Group 2

i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)

DRUG

Dose Group 3

i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)

Sponsors & Collaborators

  • MediciNova

    lead INDUSTRY

Principal Investigators

  • Michael Kalafer, MD · MediciNova

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683449 on ClinicalTrials.gov